Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Neuroimmunol ; 307: 42-46, 2017 06 15.
Article in English | MEDLINE | ID: mdl-28495137

ABSTRACT

Objective The aim of this case report is to highlight some important features of rapidly evolving Multiple Sclerosis. BACKGROUND: In a small proportion of patients, Multiple Sclerosis (MS) can present as a fulminant disease characterised by severe and frequent relapses. This form of rapidly evolving MS is associated with significant morbidity and mortality. It is therefore important to identify these patients as early as possible, so that they can be managed effectively. However, due to the rarity of fulminant forms of MS, there is limited data on the natural history and management of this condition. CASE REPORT: We present a young man with rapidly evolving Multiple Sclerosis (MS) who had 2 disabling relapses within 14weeks. He had an unusually high CSF white cell count at presentation (86per mm3; 100% lymphocytes, 97% T cells, 3% B cells), with positive oligoclonal bands. Brain MRI showed large, cavitating lesions, with no enhancement. He required a prolonged course of intravenous methyl-prednisolone and plasma exchange. CONCLUSIONS: This case suggests that male gender, young age at onset, time to second relapse, relapse severity, high CSF white cell count at presentation, large and cavitating lesions on MRI may be early predictors of rapidly evolving MS. It also highlights the therapeutic value of plasma exchange and longer courses of intravenous methylprednisolone in managing severe MS relapses. Enhancement may not always be a reliable indicator of disease activity, particularly in clinical settings where single dose gadolinium is used, due to its low sensitivity in detecting blood brain barrier leakage.


Subject(s)
Brain/diagnostic imaging , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/physiopathology , Adult , Disability Evaluation , Humans , Image Processing, Computer-Assisted , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Magnetic Resonance Imaging , Male , Multiple Sclerosis/pathology , Multiple Sclerosis/therapy
2.
Brain ; 140(2): 387-398, 2017 02.
Article in English | MEDLINE | ID: mdl-28043954

ABSTRACT

In established multiple sclerosis, tissue abnormality-as assessed using magnetization transfer ratio-increases close to the lateral ventricles. We aimed to determine whether or not (i) these changes are present from the earliest clinical stages of multiple sclerosis; (ii) they occur independent of white matter lesions; and (iii) they are associated with subsequent conversion to clinically definite multiple sclerosis and disability. Seventy-one subjects had MRI scanning a median of 4.6 months after a clinically isolated optic neuritis (49 females, mean age 33.5 years) and were followed up clinically 2 and 5 years later. Thirty-seven healthy controls (25 females, mean age 34.4 years) were also scanned. In normal-appearing white matter, magnetization transfer ratio gradients were measured 1-5 mm and 6-10 mm from the lateral ventricles. In control subjects, magnetization transfer ratio was highest adjacent to the ventricles and decreased with distance from them; in optic neuritis, normal-appearing white matter magnetization transfer ratio was lowest adjacent to the ventricles, increased over the first 5 mm, and then paralleled control values. The magnetization transfer ratio gradient over 1-5 mm differed significantly between the optic neuritis and control groups [+0.059 percentage units/mm (pu/mm) versus -0.033 pu/mm, P = 0.010], and was significantly steeper in those developing clinically definite multiple sclerosis within 2 years compared to those who did not (0.132 pu/mm versus 0.016 pu/mm, P = 0.020). In multivariate binary logistic regression the magnetization transfer ratio gradient was independently associated with the development of clinically definite multiple sclerosis within 2 years (magnetization transfer ratio gradient odds ratio 61.708, P = 0.023; presence of T2 lesions odds ratio 8.500, P = 0.071). At 5 years, lesional measures overtook magnetization transfer ratio gradients as significant predictors of conversion to multiple sclerosis. The magnetization transfer ratio gradient was not significantly affected by the presence of brain lesions [T2 lesions (P = 0.918), periventricular T2 lesions (P = 0.580) or gadolinium-enhancing T1 lesions (P = 0.724)]. The magnetization transfer ratio gradient also correlated with Expanded Disability Status Scale score 5 years later (Spearman r = 0.313, P = 0.027). An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis, is clinically relevant, and may arise from one or more mechanisms that are at least partly independent of lesion formation.


Subject(s)
Cerebral Ventricles/diagnostic imaging , Magnetic Resonance Imaging , Multiple Sclerosis/diagnostic imaging , Adult , Atrophy , Cohort Studies , Disability Evaluation , Disease Progression , Female , Humans , Image Processing, Computer-Assisted , Logistic Models , Male , Middle Aged , Multiple Sclerosis/complications , Optic Neuritis/diagnostic imaging , Optic Neuritis/etiology , Protons , White Matter/pathology , Young Adult
3.
Handb Clin Neurol ; 122: 371-91, 2014.
Article in English | MEDLINE | ID: mdl-24507526

ABSTRACT

Establishing the prognosis for multiple sclerosis (MS) early in the disease course is critically important for patients who develop this disease. Potentially, this information could be used to guide the selection of which disease modifying therapy (if any) should be started in which individual and to determine, over course of the illness, when the therapeutic approach needs to be modified. Regardless, of its importance, however, we only have a limited ability to predict how an individual's illness will evolve. For several decades, we have known about certain clinical features of MS that seem to associated with a more benign course (e.g., female gender, clinical onset before the age of 40 years, few early relapses, slow early accumulation of fixed deficits, and the initial involvement of only sensory systems). Nevertheless, the prognostic value of these clinical features offer only limited help to individual patients in making their different (and difficult) life-choices. For this reason, there have been numerous attempts to develop paraclinical tests, which can augment (and improve upon) this clinical prognostic information. These approaches have included the use of magnetic resonance imaging (MRI) measures such as gadolinium enhancement, new T2 lesions, the volume of T2 lesion burden, brain atrophy (either whole brain or separately for grey and white matter), spinal cord atrophy, cortical connectivity, and determining the characteristics and chemical composition of the normal appearing white matter. They have also included investigations of the use of immunological markers for establishing prognosis. Nevertheless, this field is still only in its infancy and our ability to predict accurately the outlook for an individual remains limited at best. This chapter reviews the current evidence, taken from both clinical and paraclinical sources, as it relates to establishing this prognosis and provides insight to where, in the future, we need to look.


Subject(s)
Multiple Sclerosis/diagnosis , Animals , Biomarkers/analysis , Early Diagnosis , Humans , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy , Multiple Sclerosis/epidemiology , Multiple Sclerosis/therapy , Prognosis
4.
J Neurol ; 255(5): 683-91, 2008 May.
Article in English | MEDLINE | ID: mdl-18274802

ABSTRACT

OBJECTIVES: To define the extent of overall brain damage in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) and to identify non-conventional magnetic resonance (MR) metrics predictive of evolution to definite MS. METHODS: Brain conventional and magnetization transfer (MT) MRI scans were obtained from 208 CIS patients and 55 matched healthy controls, recruited in four centres. Patients were assessed clinically at the time of MRI acquisition and after a median period of 3.1 years from disease onset. The following measures were derived: T2, T1 and gadolinium (Gd)- enhancing lesion volumes (LV), normalized brain volume (NBV), MTR histogram-derived quantities of the normal-appearing white matter (NAWM) and grey matter (GM). RESULTS: During the follow-up, 43 % of the patients converted to definite MS. At baseline, a significant inter-centre heterogeneity was detected for T2 LV (p = 0.003), T1 LV (p = 0.006), NBV (p < 0.001) and MTR histogram-derived metrics (p < 0.001). Pooled average MTR values differed between CIS patients and controls for NAWM (p = 0.003) and GM (p = 0.01). Gdactivity and positivity of International Panel (IP) criteria for disease dissemination in space (DIS), but not NAWM and GM MTR and NBV, were associated with evolution to definite MS. The final multivariable model retained only MRI IP criteria for DIS (p = 0.05; HR = 1.66, 95 % CI = 1.00-2.77) as an independent predictor of evolution to definite MS. CONCLUSIONS: Although irreversible tissue injury is present from the earliest clinical stages of MS, macroscopic focal lesions but not "diffuse" brain damage measured by MTR are associated to an increased risk of subsequent development of definite MS in CIS patients.


Subject(s)
Atrophy/diagnosis , Brain/pathology , Magnetic Resonance Imaging/methods , Multiple Sclerosis/diagnosis , Adult , Atrophy/physiopathology , Brain/physiopathology , Disability Evaluation , Disease Progression , Female , Humans , Image Processing, Computer-Assisted , Longitudinal Studies , Male , Mass Screening , Multiple Sclerosis/physiopathology , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Factors , Severity of Illness Index , Syndrome
5.
J Neurol ; 254(3): 306-14, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17277910

ABSTRACT

Natalizumab, an anti-alpha4 integrin antibody, significantly reduces the number of visibly enhancing multiple sclerosis (MS) lesions. In this substudy of a 2-year trial of natalizumab monotherapy versus placebo, contrast-enhanced imaging investigated for subtle blood brain barrier (BBB) leakage in relapsing remitting (RRMS) patients, and whether such leakage is modified by natalizumab. After 24 weeks on treatment, 40 patients from 3 centres (27 on natalizumab and 13 on placebo) were studied. T1 weighted images were obtained before and at set timepoints up to 46 minutes after gadolinium (Gd)-DTPA (0.3 mmol/kg to 18 patients, 0.15 mmol/kg to 22). Paired regions of interest were placed around non-enhancing lesions and contralateral normal appearing white matter (NAWM). BBB leakage was inferred through post-Gd T1 weighted signal intensity (SI) change. SI change was greater in T2 non-enhancing lesions than paired NAWM at all timepoints (P<0.005), indicating BBB leakage in lesions. No significant difference in inferred BBB leakage was observed between treatment arms as measured by SI change of lesions (P>0.05 for all timepoints, joint test P=0.24), or in SI change of NAWM (joint test P=0.37). T1 hypointense and isointense lesions exhibited similar SI changes (joint test P=0.12). There is evidence of a subtle BBB leakage within visibly non-enhancing lesions in RRMS that was not modified by alpha4 integrin blockade in this substudy cohort.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Blood-Brain Barrier/drug effects , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/pathology , Adult , Antibodies, Monoclonal, Humanized , Case-Control Studies , Double-Blind Method , Female , Follow-Up Studies , Gadolinium DTPA , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Natalizumab , Statistics, Nonparametric
6.
J Neuroimaging ; 17(1): 61-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17238871

ABSTRACT

BACKGROUND AND PURPOSE: Brain atrophy is a proposed marker of disease progression in multiple sclerosis (MS). Many magnetic resonance imaging-based methods of atrophy quantification exist, but their relative sensitivity and precision is unclear. Our aim was to compare atrophy rates from the brain boundary shift integral (BBSI), structural image evaluation, using normalization of atrophy (SIENA) (both registration-based methods) and segmented brain volume difference, in patients with clinically isolated syndromes (CIS), relapsing remitting MS (RRMS), and controls. METHODS: Thirty-seven CIS patients, 30 with early RRMS and 16 controls had T1-weighted volumetric imaging at baseline and 1 year. Brain atrophy rates were determined using segmented brain volume difference, BBSI, and SIENA. RESULTS: BBSI and SIENA were more precise than subtraction of segmented brain volumes and were more sensitive distinguishing RRMS subjects from controls. A strong correlation was observed between BBSI and SIENA. Atrophy rates were greater in CIS and RRMS subjects than controls (RRMS P < .001). With all methods, significantly greater atrophy rates were observed in CIS patients who developed clinically definite MS relative to subjects who did not. CONCLUSION: Registration-based techniques are more precise and sensitive than segmentation-based methods in measuring brain atrophy, with BBSI and SIENA providing comparable results.


Subject(s)
Brain/pathology , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Multiple Sclerosis, Relapsing-Remitting/pathology , Adult , Atrophy , Disease Progression , Female , Humans , Image Processing, Computer-Assisted/methods , Male , Middle Aged , Syndrome
7.
Brain ; 129(Pt 4): 1031-9, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16495327

ABSTRACT

Patients with clinically isolated syndromes suggestive of multiple sclerosis have evidence for abnormality in normal appearing grey matter detected using the magnetization transfer ratio (MTR), a quantitative MRI measure. One potential mechanism for the decreased grey matter MTR (GM MTR) observed is trans-synaptic morphological abnormality secondary to demyelinating lesions that are in an anatomically linked pathway but remote location. We investigated this potential association by studying the location of abnormalities using voxel-based analysis of GM MTR maps in a group of 80 patients studied within 6 months of presenting with isolated optic neuritis and compared the findings with those seen in 50 age- and sex-matched healthy controls. Occipital cortex and whole brain analysis comparing all optic neuritis patients and controls revealed a selective decrease of MTR bilaterally in the visual cortex in patients [Brodmann area (BA) 17]. Whole brain analysis of patients fulfilling the McDonald criteria for multiple sclerosis (n = 20) showed a lower MTR compared to controls bilaterally in the visual cortex (BA 17/18), left hippocampus, bilateral superior temporal gyrus, bilateral lenticular nuclei and the right cerebellum. There was no significant difference in the percentage of grey matter between patients and controls in the regions of abnormal MTR detected in the visual cortex. The intrinsic MTR decrease seen in patients suggests that there are structural changes in the visual cortex following an attack of optic neuritis. Potential mechanisms for this include trans-synaptic neuronal degeneration and cortical synaptic morphological changes; such abnormalities may also contribute to MTR abnormalities observed in the normal appearing grey matter in multiple sclerosis.


Subject(s)
Optic Neuritis/pathology , Visual Cortex/pathology , Adult , Brain/pathology , Brain Mapping/methods , Female , Humans , Image Processing, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/complications , Multiple Sclerosis/pathology , Occipital Lobe/pathology , Optic Neuritis/etiology , Prospective Studies , Visual Pathways/pathology
8.
Lancet Neurol ; 5(3): 221-7, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16488377

ABSTRACT

BACKGROUND: The McDonald International Panel accepted the Barkhof/Tintoré criteria for providing MRI evidence of dissemination in space to allow a diagnosis of multiple sclerosis in patients with clinically isolated syndromes (CIS). We applied these criteria in a large cohort of patients with CIS, representative of those seen in a general diagnostic setting, to assess their accuracy in predicting conversion to definite multiple sclerosis and to identify factors that affect this risk. METHODS: In a collaborative study of seven centres, baseline MRI and clinical follow-up data for 532 patients with CIS were studied, with the development of a second clinical event used as the main outcome. All scans were scored for lesion counts and spatial lesion distribution to assess the fulfilment--ie, at least three out of four--of the Barkhof/Tintoré criteria. We used survival analysis and 2x2 tables to assess the test characteristics of the criteria at baseline. FINDINGS: Overall conversion rate was 32.5% with a median survival time of 85.3 months. Fulfilment of the criteria at baseline showed, after a survival time of 2 years, a conversion rate of about 45% (95% CI 37-53) versus about 10% (6-16) in those with no asymptomatic lesions at baseline (p<0.0001). For patients with a follow-up of at least 2 years, the fulfilment of the MRI criteria showed an accuracy of 68% (sensitivity 49%, specificity 79%) for predicting conversion and an increase in risk of nearly four times for conversion compared with those not fulfilling the criteria (odds ratio 3.7, 95% CI 2.3-5.9; p<0.0001). Cox proportional hazards regression analysis accorded with this increased risk. No effects were recorded on the performance of the criteria by sex, presenting symptoms, or centre. Age at baseline did have a small but significant effect as predictor (hazard ratio 0.97, 0.95-0.99; p=0.002), but did not affect the prognostic value of the MRI criteria. INTERPRETATION: MRI abnormalities have important prognostic value. The cut-off, based on the Barkhof/Tintoré criteria, as incorporated in the McDonald diagnostic scheme yields acceptable specificity, but could have lower sensitivity than previously reported.


Subject(s)
Magnetic Resonance Imaging , Multiple Sclerosis/pathology , Adolescent , Adult , Child , Cohort Studies , Confidence Intervals , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Sclerosis/diagnosis , Odds Ratio , Predictive Value of Tests , Proportional Hazards Models , Reproducibility of Results , Risk , Risk Factors , Sensitivity and Specificity , Survival Analysis , Syndrome
9.
Brain ; 127(Pt 5): 1101-7, 2004 May.
Article in English | MEDLINE | ID: mdl-14998914

ABSTRACT

While brain atrophy occurs early in the clinical course of multiple sclerosis, exactly how early, which tissues are affected and the rate at which early atrophy occurs are unclear. Regional brain atrophy was investigated in 58 patients recruited within 3 months of onset of a clinically isolated syndrome (CIS) suggestive of multiple sclerosis, who were followed-up for 3 years. At 3 years, 31 subjects had developed multiple sclerosis as defined by the McDonald criteria, while 27 had not (13 had MRI-visible brain lesions and 14 did not). In those who developed multiple sclerosis, the mean decrease in grey matter fractional volume (GMF, as a fraction of total intracranial volume) was -0.017 (-3.3%) and was significantly larger than in the combined lesion-positive and lesion-negative CIS subjects [-0.005 (-1.1%), P = 0.001]. No decrease in white matter fractional volumes (WMF) was seen. Change in GMF correlated only modestly with the change in T2 lesion volume from baseline to year 3 (r = -0.428, P = 0.004). These results suggest that progressive grey matter, but not white matter, atrophy is seen in the earliest clinically observable stages of relapse onset multiple sclerosis, and this is only moderately related to lesion accumulation. Longer-term follow-up is required to determine whether early grey matter atrophy is associated with subsequent disability or cognitive impairment.


Subject(s)
Brain/pathology , Multiple Sclerosis/pathology , Adolescent , Adult , Disease Progression , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Middle Aged
10.
Ann Neurol ; 53(5): 673-6, 2003 May.
Article in English | MEDLINE | ID: mdl-12731004

ABSTRACT

In clinically isolated syndromes, the new McDonald criteria for multiple sclerosis diagnosis require new gadolinium-enhancing lesions for dissemination in time at a 3-month follow-up magnetic resonance imaging scan. In a cohort of 56 patients, these criteria were specific (95%) but less sensitive (58%) for clinically definite multiple sclerosis at 3 years. If new T2 lesions were allowed as an alternative for dissemination in time, sensitivity increased (74%) with maintained specificity (92%), enabling an accurate diagnosis of multiple sclerosis in more patients.


Subject(s)
Multiple Sclerosis/pathology , Adolescent , Adult , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Sensitivity and Specificity , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...